Publikationen 2024

Original- und Übersichtsarbeiten 2024

1: Bilsen MP, Conroy SP, Schneeberger C, Platteel TN, van Nieuwkoop C, Mody L, Caterino JM, Geerlings SE, Köves B, Wagenlehner F, Kunneman M, Visser LG, Lambregts MMC; UTI Reference Standard Consensus Group. A reference standard for urinary tract infection research: a multidisciplinary Delphi consensus study. Lancet Infect Dis. 2024 Aug;24(8):e513-e521. doi: 10.1016/S1473-3099(23)00778-8. Epub 2024 Mar 5. PMID: 38458204.

2: Wagenlehner FM, McGovern PC, Moeck G. Cefepime-Taniborbactam in Complicated Urinary Tract Infection. Reply. N Engl J Med. 2024 May 30;390(20):1938-1939. doi: 10.1056/NEJMc2403590. PMID: 38810202.

3: Wiedemann A, Wagenlehner F, Naber K, Strohmaier W, Vahlensieck W, Kirschner-Hermanns R, Bannowsky A, Wirz S, Salem J, Kuru T. Prophylaxe rezidivierenderHarnwegsinfektionen mit Nitroxolin – Real-World-Daten aus der ProNitrox-Studie [Prophylaxis of recurrent urinary tract infections by nitroxoline-real-world data of the ProNitrox study]. Urologie. 2025 Jul 28. German. doi: 10.1007/s00120-025-02641-2. Epub ahead of print. PMID: 40719777.

4: Farzat M, Wagenlehner FM. Mastering the robot-assisted pyeloplasty learning curve: analysis of operative efficiency, safety, and functional outcomes. J Robot Surg. 2025 Jul 15;19(1):394. doi: 10.1007/s11701-025-02562-4. PMID: 40665065; PMCID: PMC12263749.

5: Gupta K, Wagenlehner F, Wilcox M, Advani SD, Bilsen M, Bonkat G, Cantón R, Geerlings S, Grabein B, Horcajada JP, Kushner P, Narayanan N, Scheetz M. Urinary tract infection in adults: gaps in current guidelines - opinions from an international multidisciplinary panel and relevance to clinical practice. BMC Proc. 2025 Jul 3;19(Suppl 16):18. doi: 10.1186/s12919-025-00333-5. PMID: 40604992; PMCID: PMC12224355.

6: Wagenlehner F, Perry CR, Hooton TM, Scangarella-Oman NE, Millns H, Janmohamed S, Kramer M, Kushner P, Powell M, Jarvis E, Dennison J, Sheets A, Butler D, Breton J. Plain language summary: efficacy and safety of gepotidacin, a new oral antibiotic, compared with nitrofurantoin, a commonly used oral antibiotic, for treating uncomplicated urinary tract infection. Future Microbiol. 2025 Mar;20(4):265-275. doi: 10.1080/17460913.2025.2460387. 39988828; PMCID: PMC11951693.

7: Werneburg GT, Wagenlehner F, Clemens JQ, Harding C, Drake MJ. Towards a Reference Standard Definition of Urinary Tract Infection for Research. Eur Urol Focus. 2025 Jan;11(1):71-75. doi: 10.1016/j.euf.2024.09.010. Epub 2024 Sep 25. PMID: 39322455.

8: Wolff I, Büchner M, Hauner K, Wagenlehner F, Burchardt M, Abele-Horn M, Wullich B, Gilfrich C, Pilatz A, May M. Infectious complications following transperineal prostate biopsy with or without periprocedural antibiotic prophylaxis-a systematic review including meta-analysis of all comparative studies. Prostate Cancer Prostatic Dis. 2024 Dec 31. doi: 10.1038/s41391-024-00934-9. Epub ahead of print. PMID: 39741175.

9: von Vietinghoff S, Wagenlehner F. Was ist gesichert in der Therapie der komplizierten Harnwegsinfektionen [What is confirmed in therapy of complicated urinary tract infections]. Inn Med (Heidelb). 2024 Dec;65(12):1180-1187. German. doi: 10.1007/s00108-024-01792-2. Epub 2024 Sep 27. PMID: 39331061.

10: Farzat M, Leyh-Bannurah SR, Wagenlehner FM. Robotic surgery of the urothelial carcinoma of the upper urinary tract single surgeon initial experience, 66 consecutive cases. BMC Urol. 2024 Nov 1;24(1):238. doi: 10.1186/s12894-024-01629-y. PMID: 39482641; PMCID: PMC11529183.

11: Hartmann J, Fritzenwanker M, Imirzalioglu C, Hain T, Michael Arneth B, Wagenlehner F. Point-of-care Testing in Complicated Urinary Tract Infection: Evaluation of the Vivalytic One Urinary Tract Infection Analyser for Detecting Uropathogenic Bacteria and Antimicrobial Resistance in Urine Samples of Urological Patients in a Point-of-care Setting. Eur Urol Focus. 2024 Sep;10(5):734-741. doi: 10.1016/j.euf.2024.09.018. Epub 2024 Oct 17. PMID: 39419727.

12: Drake MJ, Wagenlehner F. Challenges in Urinary Tract Infection and the Ongoing Quest for Solutions. Eur Urol Focus. 2024 Sep;10(5):681-682. doi: 10.1016/j.euf.2024.10.001. Epub 2024 Oct 12. PMID: 39396892.

13: Vogel C, Rox K, Wagenlehner F, Titz A. Glycomimetics as Candidates for Treatment and Prevention of Catheter-associated Biofilms Formed by Pseudomonas aeruginosa. Eur Urol Focus. 2024 Sep;10(5):720-721. doi: 10.1016/j.euf.2024.08.011. Epub 2024 Sep 7. PMID: 39244510.

14: Voss H, Robert Engel D, Wagenlehner F, Shevchuk O. Discovery of Antimicrobial Peptides in Urinary Tract Infections. Eur Urol Focus. 2024 Sep;10(5):710-712. doi: 10.1016/j.euf.2024.08.010. Epub 2024 Sep 2. PMID: 39227205.

15: Wagenlehner F. Novel Antibiotics for Urinary Tract Infection (UTI): The EAGLE 2 and EAGLE-3 Trials for Uncomplicated UTI, and the CERTAIN-1 Trial for Complicated UTI. Eur Urol Focus. 2024 Sep;10(5):694-696. doi: 10.1016/j.euf.2024.07.014. Epub 2024 Aug 6. PMID: 39112136.

16: Aust AC, Weigel M, Herrmann JP, Shevchuk O, Robert Engel D, Dobrindt U, Hain T, Wagenlehner F. Influence of Kidney Environment Parameters on Antibiotic Efficacy Against Uropathogenic Escherichia coli. Eur Urol Focus. 2024 Sep;10(5):742-750. doi: 10.1016/j.euf.2024.07.007. Epub 2024 Aug 1. PMID: 39089966.

17: Bonkat G, Wagenlehner F, Kranz J. Keep it Simple: A Proposal for a New Definition of Uncomplicated and Complicated Urinary Tract Infections from the EAU Urological Infections Guidelines Panel. Eur Urol. 2024 Sep;86(3):195-197. doi: 10.1016/j.eururo.2024.05.007. Epub 2024 May 13. PMID: 38744631.

18: Rosellen J, Hauptmann A, Wag enlehner F, Diemer T. Erratum zu: Priapismus. Urologie. 2024 Aug;63(8):794. German. doi: 10.1007/s00120-024-02393-5. Erratum for: Urologie. 2024 Jun;63(6):566-572. doi: 10.1007/s00120-024-02338-y. PMID: 38980321.

19: Bester B, Koslowa K, Gronau AC, Mietens A, Nowell C, Whittaker MR, Pilatz A, Wagenlehner F, Exintaris B, Middendorff R. The oxytocin antagonist cligosiban reduces human prostate contractility: Implications for the treatment of benign prostatic hyperplasia. Br J Pharmacol. 2024 Aug;181(16):2869-2885. doi: 10.1111/bph.16369. Epub 2024 Apr 27. PMID: 38676555.

20: Kothalawala SD, Günther S, Schuppe HC, Pilatz A, Wagenlehner F, Kliesch S, O'Donnell L, Fietz D. Identification of differentially expressed genes in human testis biopsies with defective spermatogenesis. Reprod Med Biol. 2024 Dec 15;23(1):e12616. doi: 10.1002/rmb2.12616. PMID: 39677330; PMCID: PMC11646353.

21: Moeck G, Gasink LB, Mendes RE, Woosley LN, Dorr M, Chen H, Wagenlehner FM, Henkel T, McGovern PC. Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0023624. doi: 10.1128/aac.00236-24. PMID: 38780262; PMCID: PMC11232400.

22: Kranz J, Bartoletti R, Bruyère F, Cai T, Geerlings S, Köves B, Schubert S, Pilatz A, Veeratterapillay R, Wagenlehner FME, Bausch K, Devlies W, Horváth J, Leitner L, Mantica G, Mezei T, Smith EJ, Bonkat G. European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines. Eur Urol. 2024 Jul;86(1):27-41. doi: 10.1016/j.eururo.2024.03.035. Epub 2024 May 6. PMID: 38714379.

23: Dittmar F, Rosellen J, Reiser L, Fritzenwanker M, Hauptmann A, Diemer T, Schuppe HC, Wagenlehner F, Pilatz A. Comprehensive evaluation of hematospermia in patients with acute epididymitis compared to patients with isolated hematospermia. Andrology. 2024 Jul;12(5):1001-1011. doi: 10.1111/andr.13489. Epub 2023 Jul 11. PMID: 37401133.

24: Rosellen J, Hauptmann A, Wagenlehner F, Diemer T. Priapismus [Priapism]. Urologie. 2024 Jun;63(6):566-572. German. doi: 10.1007/s00120-024-02338-y. Epub 2024 Apr 23. Erratum in: Urologie. 2024 Aug;63(8):794. doi: 10.1007/s00120-024-02393-5. PMID: 38653788.

25: Islam R, Heyer J, Figura M, Wang X, Nie X, Nathaniel B, Indumathy S, Hartmann K, Pleuger C, Fijak M, Kliesch S, Dittmar F, Pilatz A, Wagenlehner F, Hedger M, Loveland B, Hotaling JH, Guo J, Loveland KL, Schuppe HC, Fietz D. T cells in testicular germ cell tumors: new evidence of fundamental contributions by rare subsets. Br J Cancer. 2024 Jun;130(12):1893-1903. doi: 10.1038/s41416-024-02669-9. Epub 2024 Apr 22. PMID: 38649788; PMCID: PMC11183042.

26: Stangl F, Wagenlehner F, Schneidewind L, Kranz J. Urosepsis: Pathophysiologie, Diagnose und Management – ein Update [Urosepsis: pathophysiology, diagnosis, and management-an update]. Urologie. 2024 Jun;63(6):543-550. German. doi: 10.1007/s00120-024-02336-0. Epub 2024 Apr 19. PMID: 38639782.

27: Engel DR, Wagenlehner FME, Shevchuk O. Scientific Advances in Understanding the Pathogenesis, Diagnosis, and Prevention of Urinary Tract Infection in the Past 10 Years. Infect Dis Clin North Am. 2024 Jun;38(2):229-240. doi: 10.1016/j.idc.2024.03.002. Epub 2024 Apr 4. PMID: 38575493.

28: Cai T, Tamanini I, Odorizzi K, Gallelli L, Lanzafame M, Mazzoli S, Lanzafame P, Massidda O, Palmieri A, Wagenlehner FME, Bjerklund Johansen TE, De Nunzio C. The diagnostic yield of the Meares & Stamey test can be significantly improved by symptom-based patient selection and the experience of the test performer. Prostate Cancer Prostatic Dis. 2024 Jun;27(2):300-304. doi: 10.1038/s41391-024-00824-0. Epub 2024 Mar 30. PMID: 38555411.

29: Cai T, Alidjanov J, Palagin I, Medina-Polo J, Nickel JC, Wagenlehner FME. Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): look to the future. Prostate Cancer Prostatic Dis. 2024 Jun;27(2):239-241. doi: 10.1038/s41391-023-00645-7. PMID: 36631538.

30: Schmiemann G, Kranz J, Mandraka F, Schubert S, Wagenlehner F, Gágyor I. The Diagnosis, Treatment, and Prevention of Recurrent Urinary Tract Infection. Dtsch Arztebl Int. 2024 May 31;121(11):373-382. doi: 10.3238/arztebl.m2024.0068. PMID: 38686602; PMCID: PMC11539874.

31: Lodise TP, Das AF, Frimodt-Møller N, Gupta K, Rodvold KA, Santerre Henriksen A, Sommer MOA, Wagenlehner F, Kaye KS. Pivmecillinam for Treatment of Uncomplicated Urinary Tract Infection: New Efficacy Analysis. Clin Infect Dis. 2025 Jun 26:ciaf280. doi: 10.1093/cid/ciaf280. Epub ahead of print. PMID: 40567143.

32: Rosellen J, Dittmar F, Hauptmann A, Diemer T, Schuppe HC, Schagdarsurengin U, Fritzenwanker M, Wagenlehner F, Pilatz A. Impaired Semen Quality in Patients with Chronic Prostatitis. J Clin Med. 2024 May 14;13(10):2884. doi: 10.3390/jcm13102884. PMID: 38792425; PMCID: PMC11122295.

33: Medina-Polo J, Falkensammer E, Köves B, Kranz J, Tandogdu Z, Tapia AM, Cai T, Wagenlehner FME, Schneidewind L, Bjerklund Johansen TE; UTISOLVE Research Group. Systematic Review and Meta-Analysis Provide no Guidance on Management of Asymptomatic Bacteriuria within the First Year after Kidney Transplantation. Antibiotics (Basel). 2024 May 14;13(5):442. doi: 10.3390/antibiotics13050442. PMID: 38786170; PMCID: PMC11117648.

34: Tandogdu Z, Koves B, Ristovski S, Balci MBC, Rennesund K, Gravas S, Nale D, Medina-Polo J, Garabášová MK, Costantini E, Cano-Valasco J, Glavinova MS, Bruyere F, Perepanova T, Kulchavenya E, Cek M, Wagenlehner F, Johansen TEB; SERPENS Investigators. Urosepsis 30-day mortality, morbidity, and their risk factors: SERPENS study, a prospective, observational multi-center study. World J Urol. 2024 May 10;42(1):314. doi: 10.1007/s00345-024-04979-2. PMID: 38730089; PMCID: PMC11087335.

35: Naber KG, Alidjanov JF, Fünfstück R, Strohmaier WL, Kranz J, Cai T, Pilatz A, Wagenlehner FM. Therapeutic strategies for uncomplicated cystitis in women. GMS Infect Dis. 2024 Apr 29;12:Doc01. doi: 10.3205/id000086. PMID: 38764941; PMCID: PMC11099625.

36: Petros P, Bornstein J, Scheffler K, Wagenlehner F, Abendstein B, Zaytseva A. Chronic pelvic pain of "unknown origin" in the female. Ann Transl Med. 2024 Apr 22;12(2):26. doi: 10.21037/atm-23-1758. Epub 2024 Apr 15. PMID: 38721452; PMCID: PMC11075965.

37: Hodgson R, Wagenlehner F, Del Amo E, Inoue H, Abendstein B. Descending perineal syndrome cure by deep transversus perinei ligament repair: surgical options. Ann Transl Med. 2024 Apr 22;12(2):32. doi: 10.21037/atm-23-1803. Epub 2024 Apr 18. PMID: 38721449; PMCID: PMC11075953.

38: Farzat M, Wagenlehner FM. On the relationship between various anticoagulants and robot-assisted radical prostatectomy: a single-surgeon serial analysis. J Robot Surg. 2024 Apr 13;18(1):174. doi: 10.1007/s11701-024-01933-7. PMID: 38613654; PMCID: PMC11016122.

39: Von Vietinghoff S, Shevchuk O, Dobrindt U, Engel DR, Jorch SK, Kurts C, Miethke T, Wagenlehner F. The global burden of antimicrobial resistance - urinary tract infections. Nephrol Dial Transplant. 2024 Mar 27;39(4):581-588. doi: 10.1093/ndt/gfad233. PMID: 37891013.

40: Wagenlehner F, Perry CR, Hooton TM, Scangarella-Oman NE, Millns H, Powell M, Jarvis E, Dennison J, Sheets A, Butler D, Breton J, Janmohamed S. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. Lancet. 2024 Feb 24;403(10428):741-755. doi: 10.1016/S0140-6736(23)02196-7. PMID: 38342126.

41: Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, Dane A, Henkel T; CERTAIN-1 Study Team. Cefepime-Taniborbactam in Complicated Urinary Tract Infection. N Engl J Med. 2024 Feb 15;390(7):611-622. doi: 10.1056/NEJMoa2304748. PMID: 38354140.

42: Farzat M, Wagenlehner FM. How Might the Number of Lymph Nodes Removed during RARP Impact the Postoperative Outcomes? Urol Int. 2024;108(3):175-182. doi: 10.1159/000536317. Epub 2024 Feb 5. PMID: 38316122; PMCID: PMC11151957.

43: Bausch K, Mantica G, Smith EJ, Bartoletti R, Bruyère F, Cai T, Geerlings S, Kranz J, Köves B, Pilatz A, Schubert S, Veeratterapillay R, Wagenlehner F, Gupta N, Bonkat G. Genitourinary Tuberculosis: A Brief Manual for Urologists on Diagnosis and Treatment from the European Association of Urology Urological Infections Panel. Eur Urol Focus. 2024 Jan;10(1):77-79. doi: 10.1016/j.euf.2023.07.006. Epub 2023 Aug 2. PMID: 37541917.

44: Mazuski JE, Wagenlehner F, Torres A, Carmeli Y, Chow JW, Wajsbrot D, Stone GG, Irani P, Bharucha D, Cheng K, Tawadrous M. Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. Infect Dis Ther. 2021 Dec;10(4):2399-2414. doi: 10.1007/s40121-021-00506-7. Epub 2021 Aug 10. PMID: 34374952; PMCID: PMC8353612.

45: Protamine 2 deficiency results in Septin 12 abnormalities. Sanovec O, Frolikova M, Kraus V, Vondrakova J, Qasemi M, Spevakova D, Simonik O, Moritz L, Caswell DL, Liska F, Ded L, Cerny J, Avidor-Reiss T, Hammoud SS, Schorle H, Postlerova P, Steger K, Komrskova K. Front Cell Dev Biol. 2024 Oct 25;12:1447630. https://doi.org/10.3389/fcell.2024.1447630

46: 17α-Ethynylestradiol alters testicular epigenetic profiles and histone-to-protamine exchange in mice. Ded L, Zatecka-Lanska E, Vaculikova E, Frolikova M, Sanovec O, Palenikova V, Simonik O, Dorosh A, Margaryan H, Elzeinova F, Kubatova A, Peknicova J, Paradowska-Dogan A, Steger K, Komrskova K. Reprod Biol Endocrinol. 2024 Nov 4;22(1):135. https://doi.org/10.1186/s12958-024-01307-6